DICP OpenIR
学科主题物理化学
INHIBITION OF CURCUMENOL TO HUMAN LIVER CYTOCHROME P450 ENZYMES
Sun DX(孙冬雪); Fang ZZ(房中则); Zhang YY(张延延); Yang L(杨凌); Ling Yang
会议名称International Society for the Study of Xenobiotics
会议日期2009-10-18
2009-10-18
会议地点美国
页码151/1
部门归属十八室
主办者AllChemie Inc.
英文摘要Abstract: Curcumenol, one of the major components of Zedoary Turmeric Oil, has been widely used to treat cancer and inflammation. In Chinese Pharmacopoeia, curcumenol is also recognized as a phytochemical marker for the quality control of Zedoary Turmeric Oil. As antibiotics or anticancer drug, curcumenol is highly likely to be used in combination with various synthetic drugs in most cases, thus it is necessary to evaluate potential pharmacokinetic drug-drug interactions induced by curcumenol. In this article the inhibition of curcumenol to seven CYP isoforms was investigated and the results demonstrated that only CYP3A4 was strongly inhibited (IC50=15.6±0.1 μM). Kinetic analyses showed the inhibition type was competitive with Ki value of 11.6 μM. Time- and NADPH-dependent inhibitions were also investigated to show curcumenol is not a mechanism-based inhibitor. Employing these in vitro data and dog’s in vivo pharmacokinetic data, [I]/Ki was predicted to be 0.00156 which suggested that curcumenol as antibiotics and antitumor agent may be safely used without inducing drug-drug interaction. Nevertheless, due to the limited pharmacokinetic data of Curcumenol in humans, it is nigh impossible to evaculate its potential effects to human from in vitro data. Further work will be done in the future.
语种中文
WOS记录号WOS:000280165300138
引用统计
文献类型会议论文
条目标识符http://cas-ir.dicp.ac.cn/handle/321008/113670
专题中国科学院大连化学物理研究所
通讯作者Ling Yang
推荐引用方式
GB/T 7714
Sun DX,Fang ZZ,Zhang YY,et al. INHIBITION OF CURCUMENOL TO HUMAN LIVER CYTOCHROME P450 ENZYMES[C],2009:151/1.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[孙冬雪]的文章
[房中则]的文章
[张延延]的文章
百度学术
百度学术中相似的文章
[孙冬雪]的文章
[房中则]的文章
[张延延]的文章
必应学术
必应学术中相似的文章
[孙冬雪]的文章
[房中则]的文章
[张延延]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。